Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease

BMC Genomics

Peter O’Gorman²  Paul Richardson¹  Colin Clarke⁴  Martin Clynes⁴  Kenneth C Anderson¹  Constantine Mitsiades¹  Justine Meiller⁴  Abdul Hameed³  Kay Reen Ting³  Catriona Hayes³  Paul Dowling⁴ 

[1] Department of Medicine, Harvard Medical School, Boston, USA;School of Medicine & Medical Science, University College Dublin, Dublin 4, Ireland;Mater Misericordiae University Hospital, Dublin 7, Ireland;National Institute for Cellular Biotechnology, Dublin City University, Glasnevin Dublin 9, Ireland

关键词: Proteomics;    PON1;    Mass spectrometry;    C4;    Bone disease;    Biomarkers;   

Others  :  1128452
DOI  :  10.1186/1471-2164-15-904

 received in 2014-05-12, accepted in 2014-10-03,  发布年份 2014

【 摘 要 】

Background

Bone destruction is a feature of multiple myeloma, characterised by osteolytic bone destruction due to increased osteoclast activity and suppressed or absent osteoblast activity. Almost all multiple myeloma patients develop osteolytic bone lesions associated with severe and debilitating bone pain, pathologic fractures, hypercalcemia, and spinal cord compression, as well as increased mortality. Biomarkers of bone remodelling are used to identify disease characteristics that can help select the optimal management of patients. However, more accurate biomarkers are needed to effectively mirror the dynamics of bone disease activity.

Results

A label-free mass spectrometry-based strategy was employed for discovery phase analysis of fractionated patient serum samples associated with no or high bone disease. A number of proteins were identified which were statistically significantly correlated with bone disease, including enzymes, extracellular matrix glycoproteins, and components of the complement system.

Conclusions

Enzyme-linked immunosorbent assay of complement C4 and serum paraoxonase/arylesterase 1 indicated that these proteins were associated with high bone disease in a larger independent cohort of patient samples. These biomolecules may therefore be clinically useful in assessing the extent of bone disease.

【 授权许可】

   
2014 Dowling et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Bilsky MH, Azeem S: Multiple myeloma: primary bone tumor with systemic manifestations. Neurosurg Clin N Am 2008, 19(1):31-40.
• [2]Roodman GD: Pathogenesis of myeloma bone disease. Leukemia 2009, 23(3):435-441.
• [3]Delorme S, Baur-Melnyk A: Imaging in multiple myeloma. Recent Results Cancer Res 2011, 183:133-147.
• [4]Zamagni E, Cavo M: The role of imaging techniques in the management of multiple myeloma. Br J Haematol 2012, 159(5):499-513.
• [5]Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78(1):21-33.
• [6]Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG, International Myeloma Working Group: The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010, 24(10):1700-1712.
• [7]Sfiridaki A, Miyakis S, Pappa C, Tsirakis G, Alegakis A, Kotsis V, Stathopoulos E, Alexandrakis M: Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma. J Hematol Oncol 2011, 4:22. BioMed Central Full Text
• [8]Dizdar O, Barista I, Kalyoncu U, Karadag O, Hascelik G, Cila A, Pinar A, Celik I, Kars A, Tekuzman G: Biochemical markers of bone turnover in diagnosis of myeloma bone disease. Am J Hematol 2007, 82(3):185-191.
• [9]Vallet S, Pozzi S, Patel K, Vaghela N, Fulciniti MT, Veiby P, Hideshima T, Santo L, Cirstea D, Scadden DT, Anderson KC, Raje N: A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 2011, 25(7):1174-1181.
• [10]Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D, Agnelli L, Neri A, Rizzoli V, Giuliani N: Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol 2013, 41(4):387-397.e381.
• [11]Xu DR, Su C, Zou WY, Xu HR, Huang S, Li J, Luo SK: Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010, 18(2):376-380.
• [12]Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, Bork P, von Mering C: STRING 8–a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 2009, 37(Database issue):D412-D416.
• [13]Terpos E, Christoulas D, Kastritis E, Katodritou E, Papatheodorou A, Pouli A, Kyrtsonis MC, Michalis E, Papanikolaou X, Gkotzamanidou M, Koulieris E, Gavriatopoulou M, Zervas K, Dimopoulos MA, Greek Myeloma Study Group: The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. Am J Hematol 2014, 89(1):34-40.
• [14]Søe K, Delaissé JM, Jakobsen EH, Hansen CT, Plesner T: Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer. Acta Oncol 2014, 53(4):547-556.
• [15]Castelli R, Gualtierotti R, Orofino N, Losurdo A, Gandolfi S, Cugno M: Current and Emerging Treatment Options for Patients with Relapsed Myeloma. Clin Med Insights Oncol 2013, 7:209-219.
• [16]Terpos E, Christoulas D, Kastritis E, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Gkotzamanidou M, Kanellias N, Manios E, Papadimitriou C, Dimopoulos MA: VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. Leukemia 2014, 28(4):928-934.
• [17]Schoengraf P, Lambris JD, Recknagel S, Kreja L, Liedert A, Brenner RE, Huber-Lang M, Ignatius A: Does complement play a role in bone development and regeneration? Immunobiology 2013, 218(1):1-9.
• [18]Li W, Li H, Song W, Hu Y, Liu Y, DA R, Chen X, Li Y, Ling H, Zhong Z, Zhang F: Differential diagnosis of systemic lupus erythematosus and rheumatoid arthritis with complements C3 and C4 and C-reactive protein. Exp Ther Med 2013, 6(5):1271-1276.
• [19]Ali OS, Abo-Shadi MA, Hammad LN: The biological significance of serum complements C3 and C4 in HCV-related chronic liver diseases and hepatocellular carcinoma. Egypt J Immunol 2005, 12(2):91-99.
• [20]Engström G, Hedblad B, Janzon L, Lindgärde F: Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Prev Rehabil 2007, 14(3):392-397.
• [21]Zheng MM, Zhang Z, Bemis K, Belch AR, Pilarski LM, Shively JE, Kirshner J: The systemic cytokine environment is permanently altered in multiple myeloma. PLoS One 2013, 8(3):e58504.
• [22]Mackinnon ES, El-Sohemy A, Rao AV, Rao LG: Paraoxonase 1 polymorphisms 172T → A and 584A → G modify the association between serum concentrations of the antioxidant lycopene and bone turnover markers and oxidative stress parameters in women 25-70 years of age. J Nutrigenet Nutrigenomics 2010, 3(1):1-8.
• [23]Arioz DT, Camuzcuoglu H, Toy H, Kurt S, Celik H, Erel O: Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer. Eur J Gynaecol Oncol 2009, 30(6):679-682.
• [24]Akçay MN, Yilmaz I, Polat MF, Akçay G: Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003, 50(Suppl 2):cclxxiii-cclxxv.
• [25]Han L, Xu XJ, Liang XH, Ma J: Association of paraoxonase polymorphisms with carotid artery atherosclerosis in essential hypertension patients. Genet Mol Res 2013, 12(4):5174-5185.
• [26]Toptaş B, Kurt Ö, Aydoğan HY, Yaylim I, Zeybek Ü, Can A, Agachan B, Uyar M, Özyavuz MK, Isbir T: Investigation of the common paraoxonase 1 variants with paraoxonase activity on bone fragility in Turkish patients. Mol Biol Rep 2013, 40(11):6519-6524.
• [27]Aharoni S, Aviram M, Fuhrman B: Paraoxonase 1 (PON1) reduces macrophage inflammatory responses. Atherosclerosis 2013, 228(2):353-361.
• [28]Khateeb J, Gantman A, Kreitenberg AJ, Aviram M, Fuhrman B: Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-gamma pathway. Atherosclerosis 2010, 208(1):119-125.
• [29]Kumagai T, Lee I, Ono Y, Maeno M, Takagi M: Ultrastructural localization and biochemical characterization of vitronectin in developing rat bone. Histochem J 1998, 30(2):111-119.
• [30]Seiffert D: Detection of vitronectin in mineralized bone matrix. J Histochem Cytochem 1996, 44(3):275-280.
• [31]Grzesik WJ, Robey PG: Bone matrix RGD glycoproteins: immunolocalization and interaction with human primary osteoblastic bone cells in vitro. J Bone Miner Res 1994, 9(4):487-496.
• [32]Tang CH, Yang RS, Huang TH, Liu SH, Fu WM: Enhancement of fibronectin fibrillogenesis and bone formation by basic fibroblast growth factor via protein kinase C-dependent pathway in rat osteoblasts. Mol Pharmacol 2004, 66(3):440-449.
• [33]Sottile J, Hocking DC: Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol Biol Cell 2002, 13(10):3546-3559.
• [34]Bentmann A, Kawelke N, Moss D, Zentgraf H, Bala Y, Berger I, Gasser JA, Nakchbandi IA: Circulating fibronectin affects bone matrix, whereas osteoblast fibronectin modulates osteoblast function. J Bone Miner Res 2010, 25(4):706-715.
• [35]Lund T, Abildgaard N, Andersen TL, Delaisse JM, Plesner T: Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. Eur J Haematol 2010, 84(5):412-420.